Long-Term Follow-Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss.

ABSTRACT:

Background and aims

Discontinuing nucleos(t)ide analogues (NAs) may lead to functional cure (HBsAg loss) in selected patients with chronic hepatitis B (CHB). We evaluated the rates and predictors of HBsAg loss during long-term follow-up in a prospective cohort.

Methods

This real-world extension study followed participants from a prospective trial of NA discontinuation. All patients had HBeAg-negative CHB without cirrhosis. Efficacy outcomes (including HBsAg loss and decline) and safety outcomes [including hepatitis flare and hepatocellular carcinoma (HCC)] were evaluated.

Results

Amongst 97 participants (85% Asian), with a median follow-up of 7 years, the cumulative incidence of HBsAg loss was 10%, 13% and 22% at 5, 7 and 9 years after stopping NA. HBsAg loss was asso

SUBMITTER: Hume SJ 

PROVIDER: S-EPMC12746397 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature